Results 81 to 90 of about 24,225 (232)

Inconsistent Transcriptomic Responses to Hexabromocyclododecane in Japanese Quail: A Comparative Analysis of Results From Four Different Study Designs

Environmental Toxicology and Chemistry, EarlyView.
Abstract Efforts to use transcriptomics for toxicity testing have classically relied on the assumption that chemicals consistently produce characteristic transcriptomic signatures that are reflective of their mechanism of action. However, the degree to which transcriptomic responses are conserved across different test methodologies has seldom been ...
Paul Béziers, Elena Legrand, Emily Boulanger, Niladri Basu, Jessica D. Ewald, Paula Henry, Markus Hecker, Jianguo Xia, Natalie Karouna‐Renier, Doug Crump, Jessica Head   +10 more
wiley   +1 more source

Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway [PDF]

, 2010
Autotaxin, encoded by the Enpp2 gene, generates lysophosphatidic acid (LPA) extracellularly, eliciting various cellular responses through specific LPA receptors.
Keino-Masu Kazuko, Koike Seiichi, Masu Masayuki, 桝 和子, 桝 正幸   +4 more
core   +1 more source

Structural mechanisms of potent lysophosphatidic acid receptor 1 activation by nonlipid basic agonists

Communications Biology
Lysophosphatidic acid receptor 1 (LPA1) is one of the G protein-coupled receptors activated by the lipid mediator, lysophosphatidic acid (LPA). LPA1 is associated with a variety of diseases, and LPA1 agonists have potential therapeutic value for treating
Hiroaki Akasaka, Fumiya K. Sano, Wataru Shihoya, Osamu Nureki   +3 more
doaj   +1 more source

Enhancing adult hippocampal neurogenesis with lysophosphatidic acid: a proposal for erasing cocaine contextual memory [PDF]

, 2018
Stimulating adult hippocampal neurogenesis (AHN) has been uncovered as a promising approach in the manipulation of retrograde memories. This work aims to study whether increasing AHN with lysophosphatidic acid (LPA, an endogenous lysophospholipid with ...
Castilla Ortega, María Estela, Estivill-Torrús, Guillermo, Gil Rodríguez, Sara, Ladrón de Guevara-Miranda, David, Moreno-Fernández, Román D., Pavón, Francisco Javier, Rodríguez de Fonseca, Fernando, Rosell-del-Valle, Cristina, Santin-Nuñez, Luis Javier, Serrano, Antonia   +9 more
core  

Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer [PDF]

, 2013
Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase ...
Agarwal, Anliker, Aoki, Baker, Bensaad, Cai, Carmela Ricciardelli, Carmen Pyragius, Chae, Chajes, Chang, Choi, Daly, Dong, Eck, Eder, Fishman, Gansler, Gatt, Hanada, Hu, Hu, Illuzzi, Imamura, Iwasawa, Jeong, Jiang, Kimura, Kushi, La Vecchia, Lee, Lee, Li, Little, Makhlouf, Maria Fuller, Martin Oehler, Menendez, Migita, Mukherjee, Murthi, Nakamura, Nam, Nam, Nieman, Noguchi, Pan, Pewzner-Jung, Pizer, Ptaszynska, Pustilnik, Radin, Rahman, Ren, Risch, Risch, Ryland, Sawada, Selzner, Shida, Shintani, Siegel, Song, Spiegel, Sutphen, Swanton, Swinnen, Swinnen, Tania, Tokumura, Tomek, Ueda, Umezu-Goto, Van Vlerken, Vidot, Von Haefen, Wang, Watanabe, Xiao, Xu, Xu, Yanagida, Yang, Yu, Zhang, Zhou, Zhou   +86 more
core   +3 more sources

CYRI-B-mediated macropinocytosis drives metastasis via lysophosphatidic acid receptor uptake

eLife
Pancreatic ductal adenocarcinoma carries a dismal prognosis, with high rates of metastasis and few treatment options. Hyperactivation of KRAS in almost all tumours drives RAC1 activation, conferring enhanced migratory and proliferative capacity as well ...
Savvas Nikolaou, Amelie Juin, Jamie A Whitelaw, Nikki R Paul, Loic Fort, Colin Nixon, Heather J Spence, Sheila Bryson, Laura M Machesky   +8 more
doaj   +1 more source

In vitro pharmacological characterization of standard and new lysophosphatidic acid receptor antagonists using dynamic mass redistribution assay

Frontiers in Pharmacology, 2023
Lysophosphatidic acid (LPA) is a bioactive phospholipid that acts as an agonist of six G protein-coupled receptors named LPA receptors (LPA1-6).
C. Ruzza, C. Ruzza, M. Argentieri, F. Ferrari, E. Armani, M. Trevisani, G. Marchini, G. Calo’   +7 more
doaj   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Structural identification of oxidized acyl-phosphatidylcholines that induce platelet activation [PDF]

, 2005
Oxidation of low-density lipoprotein (LDL) generates proinflammatory and prothrombotic mediators that may play a crucial role in cardiovascular and inflammatory diseases.
Berliner JA, Bittman R, Casals-Stenzal J, Esterbauer H, Fernandez-Ortiz A, Frey B, Goetzl EJ, Holvoet P, Itabe H, Kamido H, Kamido H, Kern H, Kinsella BT, Kitagawa S, O'Flaherty JT, O'Flaherty JT, Rasmussen UB, Sevanian A, Subbanagounder G, Tanaka T, Trip MD, Volf I, Watson AD, Weidtmann A   +23 more
core   +1 more source

Novel lysophosphoplipid receptors: their structure and function

Journal of Lipid Research, 2014
It is now accepted that lysophospholipids (LysoGPs) have a wide variety of functions as lipid mediators that are exerted through G protein-coupled receptors (GPCRs) specific to each lysophospholipid.
Kumiko Makide, Akiharu Uwamizu, Yuji Shinjo, Jun Ishiguro, Michiyo Okutani, Asuka Inoue, Junken Aoki   +6 more
doaj   +1 more source